Namyang Dairy saw a surge in its shares after claiming its Bulgaris yogurt variants can help lower the risk of COVID-19 infection. The company's day trading on Wednesday, April 14, reportedly increased.
As per The Korea Herald, Namyang Dairy’s shares once shot up by 28.68% to KRW489,000 or around $437.39 in the early morning trading. It was added that within 20 minutes after the opening bell, the company’s preferred stocks also surge by the daily allowable limit of 29.78% to reach KRW231,000.
Prior to Wednesday’s results, it was reported that the firm’s shares went up 7.19% and 6.71% on Friday and Monday, respectively. It then increased again by 8.57% on Tuesday, and this shows that Namyang Dairy’s shares have been on the rise since last weekend and continued this week.
Namyang’s COVID-19 claim
Observers are saying that the company’s surge in shares may be due to its claims that its Bulgaris yogurt lineup can help reduce the risk of getting COVID-19. Some market insiders also think that some investors may have also used information that caused the hike in the recent stock tradings.
At any rate, what triggered the sudden increase in shares of Namyang Dairy was the statement given by the company during a news conference in Seoul.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Namyang’s chief of antiviral immune research center, Park Jong Su, said at that time. “Our experiments showed that Bulgaris helped remove the Influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
He added that the test of the yogurt’s effectiveness in fighting coronavirus was done using the lung cells of a monkey. As a result of this claim, people reportedly rushed out to purchase Namyang Dairy’s Bulgaris yogurts in stores.
Statement from S. Korea’s health officials
After the announcement from Namyang, the public health authorities released a statement. The agency expressed its concern over the claims.
“The latest research result has not proved to be effective in eliminating those viruses in the human body,” the Korea Disease Control and Prevention Agency stated. “Therefore, it is hard to say whether it can serve as an actual prevention or treatment measure for (the viruses).”


Iran Targets U.S. Bases in Bahrain, Kuwait as Hormuz Conflict Escalates and Oil Prices Jump
Cuba Power Outage Sparks Havana Protests as Fuel Crisis Deepens
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
US Back-to-School Spending Seen Falling as Families Focus on Essentials
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Asian Stocks Slip as Iran Tensions, Samsung Weakness and Fed Caution Weigh on Markets
Oil Prices Rise as U.S.-Iran Conflict Fuels Strait of Hormuz Supply Fears
RBNZ Raises Interest Rates to 2.50%, Signals More Tightening as Inflation Risks Persist
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Venezuela Earthquake Death Toll Climbs to 3,811 as Government Seeks Sanctions Relief
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 



